RxDoctor Payments Data

Maurie Markman

Gynecologic Oncology · Houston, TXNPI 1669564696

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (49.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AstraZeneca at 34.9% of the total. Reporting peaked in 2019 at $84,350 and has fallen 98.1% since, to $1,600 in 2025. Among gynecologic oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$203,917in general payments, 2019–2025

Across 132 payments — averaging $1544.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$71K
  • GSK$54K
  • Genentech USA, Inc.$31K
  • Clovis Oncology, Inc.$20K
  • Merck$18K
  • Myriad Genetic Laboratories, Inc.$7K
  • plus $3K from 3 others

What the payments were for

  • Consulting fees$100,37549%
  • Speaking & faculty fees$86,37842%
  • Travel & lodging$15,3628%
  • Food & beverage$1,8031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$203,917 in reported general payments places this provider in the 95th percentile of 135 gynecologic oncology providers in Texas.

See all gynecologic oncology providers in Texas

Other gynecologic oncology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →